Published in Neurology on August 11, 1999
Fingolimod after natalizumab and the risk of short-term relapse. Neurology (2014) 1.96
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology (2009) 1.73
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology (2014) 1.40
Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest (2001) 1.32
Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J Biol Chem (2002) 1.16
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis (2006) 1.01
Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2009) 1.01
Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. Mult Scler (2010) 1.00
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence (2015) 0.94
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol (2013) 0.94
Current and future therapies for multiple sclerosis. Scientifica (Cairo) (2013) 0.92
Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol (2010) 0.89
Natalizumab therapy for multiple sclerosis. Neurotherapeutics (2013) 0.89
Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol (2013) 0.88
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurol (2007) 0.88
A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.88
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis (2014) 0.87
Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag (2009) 0.86
Risk acceptance in multiple sclerosis patients on natalizumab treatment. PLoS One (2013) 0.86
Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis. J Immunol Res (2014) 0.84
Anti-integrin therapy for multiple sclerosis. Autoimmune Dis (2012) 0.84
Developing therapeutics for the treatment of multiple sclerosis. NeuroRx (2005) 0.83
Natalizumab: a country-based surveillance program. Neurol Sci (2008) 0.82
A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch Med Sci (2010) 0.82
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurol Sci (2013) 0.81
Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag (2007) 0.81
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol (2014) 0.81
Innovative monoclonal antibody therapies in multiple sclerosis. Ther Adv Neurol Disord (2008) 0.80
Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol (2008) 0.79
Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ (2006) 0.79
What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol (2014) 0.79
Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (1999) 0.77
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2015) 0.77
Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology (1999) 0.76
Multiple sclerosis and the blood-central nervous system barrier. Cardiovasc Psychiatry Neurol (2013) 0.76
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
Editorial: cell movement. Br J Pharmacol (2014) 0.75
The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch. Neurol Neuroimmunol Neuroinflamm (2014) 0.75
Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. Clinicoecon Outcomes Res (2009) 0.75
A protein interaction map of Drosophila melanogaster. Science (2003) 20.06
Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med (1995) 5.73
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43
The postviral fatigue syndrome--an analysis of the findings in 50 cases. J Infect (1985) 4.39
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
The virD operon of Agrobacterium tumefaciens encodes a site-specific endonuclease. Cell (1986) 4.20
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Controlled trial prednisolone in acute polyneuropathy. Lancet (1978) 3.71
Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. BMJ (1991) 3.65
Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem (1986) 3.63
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Orbital venous anomalies. Ophthalmology (1997) 3.25
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron (1995) 3.08
Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci U S A (1986) 2.92
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med (1991) 2.92
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Myasthenia gravis. Lancet (2001) 2.82
Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 2.74
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ (1992) 2.64
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Myalgic encephalomyelitis--report of an epidemic. J R Coll Gen Pract (1983) 2.64
A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry (1988) 2.63
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med (1988) 2.60
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58
Molecular linkage underlying microtubule orientation toward cortical sites in yeast. Science (2000) 2.57
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry (1988) 2.56
Dentistry and anaesthesia. Br Dent J (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53
Epidemic myalgic encephalomyelitis. Practitioner (1980) 2.53
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry (1997) 2.52
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
Voluntary regionalization and associated trends in perinatal care: the Nova Scotia Reproductive Care Program. Am J Obstet Gynecol (1983) 2.45
Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature (1995) 2.45
Herpes simplex encephalitis. J Neurol Neurosurg Psychiatry (2002) 2.45
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) (2004) 2.37
The persistent vegetative state. BMJ (1995) 2.35
Management of acute optic neuritis. Lancet (2002) 2.33
Immunological abnormalities in patients who had the oculomucocutaneous syndrome associated with practolol therapy. Lancet (1976) 2.31
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
Comparison of Difco ESP and Organon Teknika BacT/Alert continuous-monitoring blood culture systems. J Clin Microbiol (1994) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15
Nosocomial multiply resistant Klebsiella pneumoniae: epidemiology of an outbreak of apparent index case origin. Antimicrob Agents Chemother (1979) 2.13
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology (2006) 2.10
Biodiversity of stream insects: variation at local, basin, and regional scales. Annu Rev Entomol (1998) 2.10
The symptoms of chronic fatigue syndrome are related to abnormal ion channel function. Med Hypotheses (2000) 2.10
Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry (1998) 2.07
The psychometric properties of clinical rating scales used in multiple sclerosis. Brain (1999) 2.06
The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler (1999) 2.02
Imaging in transient regional osteoporosis. Br J Rheumatol (1997) 2.01
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain (2006) 1.95
Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93
The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J Exp Med (1996) 1.93
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Relapsing polychondritis. Three cases with a clinico-pathological study and literature review. Q J Med (1972) 1.87
Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86